Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 5/20 | 0.55 |
| ▸ | CASP2 | P42575 | 1/20 | 0.51 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.51 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.51 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.50 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.50 |
| ▸ | SLC6A5 | Q9Y345 | 2/20 | 0.49 |
| ▸ | NAAA | Q02083 | 1/20 | 0.49 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | RRM1 | P23921 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7262356 | 0.97 | NOD1 (0.54) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL7262358 | 0.91 | NOD1 (0.51) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL13422874 | 0.90 | NOD1 (0.58) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL17761085 | 0.89 | NOD1 (0.56) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL2041818 | 0.87 | NOD1 (0.52) | NOD1CASP2GNAI3GNAO1GNAI1 | |
| SCHEMBL9934473 | 0.84 | SLC6A5 (0.57) | SLC6A5EPHX2 | |
| SCHEMBL9934475 | 0.84 | SLC6A5 (0.57) | SLC6A5EPHX2 | |
| SCHEMBL9933130 | 0.84 | SLC6A5 (0.57) | SLC6A5EPHX2 | |
| SCHEMBL9942237 | 0.84 | SLC6A5 (0.57) | SLC6A5EPHX2 | |
| SCHEMBL9933128 | 0.84 | SLC6A5 (0.57) | SLC6A5EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8647613-B2 | Drug carrier | JCR PHARMACEUTICALS CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-8647613-B2 | Drug carrier | JCR PHARMACEUTICALS CO., LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20090136443-A1 | Drug Carrier | OXGENIX CO., LTD. (JP) | 2009-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090136443-A1 | Drug Carrier | ABCB11, SLC47A1, SLC47A2 | NOD1 2645/4885CASP2 4139/4885GNAI3 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.